valsartan has been researched along with Diabetic Retinopathy in 7 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 5 (71.43) | 29.6817 |
| 2010's | 2 (28.57) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Coppey, LJ; Davidson, EP; Obrosov, A; Shevalye, H; Yorek, MA | 1 |
| Fan, J; Hoffman, MR; Qin, Y; Ren, H; Xu, G; Zhang, M | 1 |
| Xie, XW; Zhao, P | 1 |
| Coll, JR; Estacio, RO; Schrier, RW; Tran, ZV | 1 |
| Fletcher, EL; Phipps, JA; Wilkinson-Berka, JL | 1 |
| Jaworski, K; Ninkovic, S; Tan, G; Wilkinson-Berka, JL | 1 |
| Inoue, M; Ishida, S; Izumi-Nagai, K; Koto, T; Nagai, N; Oike, Y; Ozawa, Y; Satofuka, S; Tsubota, K; Umezawa, K; Yamashiro, K | 1 |
1 trial(s) available for valsartan and Diabetic Retinopathy
| Article | Year |
|---|---|
Effect of intensive blood pressure control with valsartan on urinary albumin excretion in normotensive patients with type 2 diabetes.
Topics: Adult; Aged; Aged, 80 and over; Albuminuria; Angiotensin II Type 1 Receptor Blockers; Blood Pressure; Cardiovascular Diseases; Colorado; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Diabetic Neuropathies; Diabetic Retinopathy; Disease Progression; Female; Follow-Up Studies; Humans; Kidney Function Tests; Male; Middle Aged; Prospective Studies; Tetrazoles; Time Factors; Treatment Outcome; Valine; Valsartan | 2006 |
6 other study(ies) available for valsartan and Diabetic Retinopathy
| Article | Year |
|---|---|
Vascular and Neural Complications in Type 2 Diabetic Rats: Improvement by Sacubitril/Valsartan Greater Than Valsartan Alone.
Topics: Aminobutyrates; Angiotensin II Type 1 Receptor Blockers; Angiotensin Receptor Antagonists; Animals; Biphenyl Compounds; Cardiovascular Agents; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diabetic Neuropathies; Diabetic Retinopathy; Diet, High-Fat; Disease Progression; Drug Combinations; Male; Neprilysin; Neural Conduction; Neuroprotective Agents; Protease Inhibitors; Rats, Sprague-Dawley; Tetrazoles; Valsartan; Vascular Resistance | 2018 |
Aquaporin changes during diabetic retinopathy in rats are accelerated by systemic hypertension and are linked to the renin-angiotensin system.
Topics: Adrenergic beta-1 Receptor Antagonists; Angiotensin II Type 1 Receptor Blockers; Animals; Aquaporins; Blotting, Western; Diabetes Mellitus, Experimental; Diabetic Retinopathy; Glial Fibrillary Acidic Protein; Hypertension; Metoprolol; Nerve Fibers; Neuroglia; Rats; Rats, Inbred WKY; Renin-Angiotensin System; Retina; Tetrazoles; Valine; Valsartan | 2012 |
[The experimental study of captopril and valsartan on the preventing and treatment of diabetic retinopathy in diabetic mice].
Topics: Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Animals; Captopril; Diabetes Mellitus, Experimental; Diabetic Retinopathy; Male; Mice; Random Allocation; Tetrazoles; Valine; Valsartan; Vascular Endothelial Growth Factor A | 2004 |
Retinal dysfunction in diabetic ren-2 rats is ameliorated by treatment with valsartan but not atenolol.
Topics: Adrenergic beta-Antagonists; Angiotensin II Type 1 Receptor Blockers; Animals; Animals, Genetically Modified; Antihypertensive Agents; Atenolol; Blood Pressure; Diabetes Mellitus, Experimental; Diabetic Retinopathy; Electroretinography; Female; Hypertension; Neuroglia; Photic Stimulation; Rats; Retina; Tetrazoles; Valine; Valsartan | 2007 |
Valsartan but not atenolol improves vascular pathology in diabetic Ren-2 rat retina.
Topics: Adrenergic beta-Antagonists; Angiotensin II Type 1 Receptor Blockers; Animals; Animals, Genetically Modified; Atenolol; Blood Pressure; Body Weight; Cell Proliferation; Diabetes Mellitus, Experimental; Diabetic Retinopathy; Endothelial Cells; Female; Glycated Hemoglobin; Rats; Rats, Sprague-Dawley; Renin; Retinal Vessels; Tetrazoles; Valine; Valsartan | 2007 |
Suppression of diabetes-induced retinal inflammation by blocking the angiotensin II type 1 receptor or its downstream nuclear factor-kappaB pathway.
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin II Type 2 Receptor Blockers; Animals; Benzamides; Blotting, Western; Cell Adhesion; Chemokine CCL2; Cyclohexanones; Diabetes Mellitus, Experimental; Diabetic Retinopathy; Enzyme-Linked Immunosorbent Assay; Imidazoles; Intercellular Adhesion Molecule-1; Leukocytes; Male; Mice; Mice, Inbred C57BL; NF-kappa B; Pyridines; Receptor, Angiotensin, Type 1; Renin-Angiotensin System; Retinitis; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Tetrazoles; Thiazolidines; Valine; Valsartan; Vascular Endothelial Growth Factor A | 2007 |